Macquarie Group’s Arcturus Therapeutics ARCT Stock Holding History

Macquarie Group’s Portfolio ARCT Stock Details ARCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-288	Closed	-$4.83K	–	2455
2022 Q2	$5K	Hold	288	–	–	﹤0.01%	2517
2022 Q1	$8K	Hold	288	–	–	﹤0.01%	2535
2021 Q4	$11K	Hold	288	–	–	﹤0.01%	2493
2021 Q3	$14K	Hold	288	–	–	﹤0.01%	2500
2021 Q2	$10K	Hold	288	–	–	﹤0.01%	2466
2021 Q1	$12K	Sell	288 -136	-32%	-$8.11K	﹤0.01%	2363
2020 Q4	$18K	Hold	424	–	–	﹤0.01%	2239
2020 Q3	$18K	Hold	424	–	–	﹤0.01%	2184
2020 Q2	$20K	Sell	424 -1,701	-80%	-$58.6K	﹤0.01%	2158
2020 Q1	$29K	Buy	+2,125	New	+$27.2K	﹤0.01%	1890

Other funds holding ARCT

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Macquarie Group's ARCT Position: Q3 2022 in Review

Macquarie Group sold out of Arcturus Therapeutics (ARCT) in Q3 2022, closing a stake of 288 shares — an estimated $4.83K sold.

Macquarie Group first reported a position in ARCT in Q1 2020 and held it in 10 quarters. The position peaked at $29K in Q1 2020. 116 funds tracked by Wall St. Rank hold ARCT as of Q3 2022.

Macquarie Group reported no remaining Arcturus Therapeutics position as of Q3 2022 after selling out during the quarter.
Macquarie Group sold 288 Arcturus Therapeutics shares in Q3 2022, an estimated $4.83K.
Macquarie Group first reported a position in Arcturus Therapeutics in Q1 2020 and held it in 10 quarters.
Macquarie Group's Arcturus Therapeutics position peaked at $29K in Q1 2020.
116 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q3 2022.

Based on Macquarie Group's 13F filing for Q3 2022, filed 14 Nov 2022.